[go: up one dir, main page]

CO2019011359A2 - Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii - Google Patents

Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii

Info

Publication number
CO2019011359A2
CO2019011359A2 CO2019011359A CO2019011359A CO2019011359A2 CO 2019011359 A2 CO2019011359 A2 CO 2019011359A2 CO 2019011359 A CO2019011359 A CO 2019011359A CO 2019011359 A CO2019011359 A CO 2019011359A CO 2019011359 A2 CO2019011359 A2 CO 2019011359A2
Authority
CO
Colombia
Prior art keywords
prognosis
gastric cancer
predicting
patients
benefit
Prior art date
Application number
CO2019011359A
Other languages
English (en)
Inventor
Jae Ho Cheong
Sung Hoon Noh
Yong Min Huh
Hyun Ki Kim
Original Assignee
Novomics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novomics Co Ltd filed Critical Novomics Co Ltd
Publication of CO2019011359A2 publication Critical patent/CO2019011359A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio II y III, y se desarrolla un algoritmo que puede predecir el pronóstico y la respuesta a quimioterapia usando resultados de análisis cuantitativo de niveles de expresión de ARNm de un grupo de genes marcadores relacionados con el pronóstico o la respuesta a quimioterapia y un grupo de genes de referencia en cáncer gástrico avanzado, y puede usarse como información complementaria para determinar un método para tratar a un paciente con cáncer gástrico.
CO2019011359A 2017-03-14 2019-10-15 Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii CO2019011359A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170032027 2017-03-14
PCT/KR2017/008781 WO2018169145A1 (ko) 2017-03-14 2017-08-11 진행성 위암 환자의 수술 후 예후 또는 항암제 적합성 예측 시스템

Publications (1)

Publication Number Publication Date
CO2019011359A2 true CO2019011359A2 (es) 2019-10-31

Family

ID=63523198

Family Applications (1)

Application Number Title Priority Date Filing Date
CO2019011359A CO2019011359A2 (es) 2017-03-14 2019-10-15 Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii

Country Status (17)

Country Link
US (1) US11732304B2 (es)
EP (1) EP3517624B1 (es)
JP (1) JP6864089B2 (es)
KR (2) KR101966642B1 (es)
CN (1) CN110168106B (es)
AU (1) AU2017403899B2 (es)
BR (1) BR112019019022A2 (es)
CA (1) CA3055735C (es)
CL (1) CL2019002633A1 (es)
CO (1) CO2019011359A2 (es)
IL (1) IL269256A (es)
MX (1) MX2019011017A (es)
NZ (1) NZ756580A (es)
PE (1) PE20191482A1 (es)
RU (1) RU2737449C1 (es)
UA (1) UA125590C2 (es)
WO (1) WO2018169145A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20191482A1 (es) 2017-03-14 2019-10-18 Novomics Co Ltd Sistema para predecir el pronostico y beneficio de una quimioterapia adyuvante para pacientes con cancer gastrico en estadio ii y iii
KR101940657B1 (ko) * 2017-04-24 2019-01-21 (주) 노보믹스 위암의 생물학적 특성에 기반한 군 구분 및 예후 예측 시스템
WO2020226333A1 (ko) * 2019-05-03 2020-11-12 주식회사 디시젠 암 예후 예측방법 및 이의 조성물
KR102324294B1 (ko) * 2019-11-19 2021-11-11 서울대학교산학협력단 상피성 난소암 예후 예측 방법 및 장치
KR102811608B1 (ko) 2020-11-20 2025-05-21 주식회사 레피다인 간암의 예후 예측을 위한 정보 제공 방법
KR102462097B1 (ko) * 2020-12-30 2022-11-02 국립암센터 삼중사중극자 다중반응 모니터링 기반 암 표적치료제 효능 예측
CN113462773A (zh) * 2021-05-19 2021-10-01 山东大学 一种预测胃癌患者生存风险、免疫治疗响应和细胞焦亡诱导剂适用性的标志物及其应用
CN114720687A (zh) * 2022-06-01 2022-07-08 浙江省肿瘤医院 Sfrp4作为胃癌预后标志物的应用
KR102865138B1 (ko) * 2022-06-14 2025-09-29 연세대학교 산학협력단 높은 sfrp4의 발현을 보이는 암의 치료방법
KR20250090657A (ko) * 2023-12-13 2025-06-20 연세대학교 산학협력단 높은 sfrp4의 발현을 보이는 암의 치료방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3388534A1 (en) * 2000-03-27 2018-10-17 Thomas Jefferson University Compositions for treating stomachal and oesophageal cancer cells
JPWO2005007846A1 (ja) 2003-04-25 2006-08-31 財団法人癌研究会 腫瘍細胞の抗癌剤に対する感受性を判定する方法
KR20080006315A (ko) * 2006-07-12 2008-01-16 삼성전자주식회사 전기 영동 장치 및 그의 제조 방법
KR101007926B1 (ko) 2006-12-27 2011-01-12 (주)레퍼런스바이오랩 표준 발현 유전자를 발굴하기 위한 유전자 발현 데이터처리, 분석 방법
NZ562237A (en) * 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
ES2689958T3 (es) * 2010-12-13 2018-11-16 Samsung Life Public Welfare Foundation Marcador para predecir el pronóstico de cáncer de estómago y procedimiento para predecir el pronóstico de cáncer de estómago
KR101416147B1 (ko) * 2012-07-18 2014-07-09 국립암센터 위암 진단 및 치료를 위한 ａｄｃｙ3의 용도
KR101504817B1 (ko) * 2013-04-05 2015-03-24 연세대학교 산학협력단 국소 진행형 위암에 대한 예후 예측 시스템
WO2015172201A1 (en) * 2014-05-16 2015-11-19 Peter Maccallum Cancer Institute Biomarker of gastric cancer
MX2017005751A (es) * 2014-11-03 2018-04-10 Genentech Inc Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
PE20191482A1 (es) 2017-03-14 2019-10-18 Novomics Co Ltd Sistema para predecir el pronostico y beneficio de una quimioterapia adyuvante para pacientes con cancer gastrico en estadio ii y iii

Also Published As

Publication number Publication date
JP6864089B2 (ja) 2021-04-21
EP3517624C0 (en) 2024-10-02
CN110168106B (zh) 2024-02-20
KR20190024923A (ko) 2019-03-08
CA3055735A1 (en) 2018-09-20
CL2019002633A1 (es) 2020-04-03
IL269256A (en) 2019-11-28
UA125590C2 (uk) 2022-04-27
EP3517624A4 (en) 2020-04-29
WO2018169145A1 (ko) 2018-09-20
KR20180105036A (ko) 2018-09-27
CN110168106A (zh) 2019-08-23
BR112019019022A2 (pt) 2020-04-22
AU2017403899B2 (en) 2021-12-09
EP3517624B1 (en) 2024-10-02
CA3055735C (en) 2021-12-14
NZ756580A (en) 2022-01-28
AU2017403899A1 (en) 2019-09-19
US20190284637A1 (en) 2019-09-19
RU2737449C1 (ru) 2020-11-30
KR102069043B1 (ko) 2020-01-22
EP3517624A1 (en) 2019-07-31
MX2019011017A (es) 2020-01-20
JP2019537436A (ja) 2019-12-26
PE20191482A1 (es) 2019-10-18
KR101966642B1 (ko) 2019-04-09
US11732304B2 (en) 2023-08-22

Similar Documents

Publication Publication Date Title
CO2019011359A2 (es) Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii
CL2020001730A1 (es) Método para el tratamiento de cáncer. (divisional solicitud 201702728)
MX2018008169A (es) Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante.
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
BR112017012222A2 (pt) métodos para derivar um biomarcador de assinatura gênica e para tratar um paciente que tem um tumor, método e sistema para testar uma amostra de tumor removida de um paciente, e, kit.
MX2017014736A (es) Metodos terapeuticos y diagnosticos para cancer.
MX2022002138A (es) Estandares de antigeno prostatico y sus usos.
MX2015004610A (es) Metodo para diagnostico, pronostico y tratamiento de metastasis de cancer de prostata usando c-maf.
MX2016014189A (es) Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antigeno 4 de linfocito t citotoxico (anti-ctla-4) para tratar el cancer de pulmon no microcitico.
BR112016007864A2 (pt) método para a prognose e tratamento de metástase de câncer
MX2017003387A (es) Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogenetica de cancer colorrectal metastasico.
CO7151491A2 (es) Método para la identificación del origen de un cancer de origen primario desconocido
SG10201908277TA (en) Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas)
MX2024001734A (es) Metodo de modificacion de diferenciacion e inmunidad de macrofagos.
MX2017000840A (es) Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer.
MX386750B (es) MARCADORES DE METILACIÓN Y DE miARN PARA LA DETECCIÓN DE CÁNCER.
BR112016007348A2 (pt) membro de ligação específica que se liga ao receptor do fator de crescimento epidérmico humano 2 (her2) para uso em um método de tratamento do câncer em um paciente, método de tratamento de câncer em um paciente, método de identificação de um câncer em um paciente, método para prognosticar a resposta de um câncer
BR112015030627A2 (pt) marcadores biológicos úteis na imunoterapia contra o câncer
MX2017013074A (es) Metodos y composiciones para prediccion de eficacia terapeutica de tratamientos contra el cancer y prognosis del cancer.
BR112015017403A2 (pt) biomarcadores de terapia de combinação de anti-tnf e anti-il17 para doença inflamatória
MX2020006297A (es) Variantes de cd19.
MX2019010150A (es) Uso de biomarcadores en la identificacion de pacientes con cancer que seran sensibles al tratamiento con un inhibidor de prmt5.
EA201692497A1 (ru) Биомаркеры ответа на ингибиторы ezh2
BR112018008799A2 (pt) método de prognóstico
BR112018067990A2 (pt) cromogranina a como um marcador para câncer de bexiga